ScinoPharm Taiwan Ltd
TWSE:1789

Watchlist Manager
ScinoPharm Taiwan Ltd Logo
ScinoPharm Taiwan Ltd
TWSE:1789
Watchlist
Price: 23.5 TWD -0.63% Market Closed
Market Cap: 18.6B TWD
Have any thoughts about
ScinoPharm Taiwan Ltd?
Write Note

ScinoPharm Taiwan Ltd
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ScinoPharm Taiwan Ltd
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
ScinoPharm Taiwan Ltd
TWSE:1789
Capital Expenditures
-NT$264.4m
CAGR 3-Years
-3%
CAGR 5-Years
-21%
CAGR 10-Years
16%
Y
YungShin Global Holding Corp
TWSE:3705
Capital Expenditures
-NT$98.1m
CAGR 3-Years
25%
CAGR 5-Years
30%
CAGR 10-Years
10%
Formosa Laboratories Inc
TWSE:4746
Capital Expenditures
-NT$567.1m
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
0%
S
SCI Pharmtech Inc
TWSE:4119
Capital Expenditures
-NT$896.9m
CAGR 3-Years
-35%
CAGR 5-Years
-34%
CAGR 10-Years
-11%
Lotus Pharmaceutical Co Ltd
TWSE:1795
Capital Expenditures
-NT$1.6B
CAGR 3-Years
-10%
CAGR 5-Years
-19%
CAGR 10-Years
-19%
Standard Chem & Pharm Co Ltd
TWSE:1720
Capital Expenditures
-NT$581m
CAGR 3-Years
-26%
CAGR 5-Years
-31%
CAGR 10-Years
-6%
No Stocks Found

ScinoPharm Taiwan Ltd
Glance View

Market Cap
18.6B TWD
Industry
Pharmaceuticals

ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.

Intrinsic Value
16.51 TWD
Overvaluation 30%
Intrinsic Value
Price

See Also

What is ScinoPharm Taiwan Ltd's Capital Expenditures?
Capital Expenditures
-264.4m TWD

Based on the financial report for Jun 30, 2024, ScinoPharm Taiwan Ltd's Capital Expenditures amounts to -264.4m TWD.

What is ScinoPharm Taiwan Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
16%

Over the last year, the Capital Expenditures growth was -4%. The average annual Capital Expenditures growth rates for ScinoPharm Taiwan Ltd have been -3% over the past three years , -21% over the past five years , and 16% over the past ten years .

Back to Top